{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T19:13:07Z","timestamp":1790363587615,"version":"4.1.0"},"reference-count":69,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100011110","name":"UCB","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011110","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Joint Bone Spine"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1016\/j.jbspin.2018.01.006","type":"journal-article","created":{"date-parts":[[2018,3,8]],"date-time":"2018-03-08T14:39:33Z","timestamp":1520519973000},"page":"275-284","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":90,"title":["2018 update of French Society for Rheumatology (SFR) recommendations about the everyday management of patients with spondyloarthritis"],"prefix":"10.1016","volume":"85","author":[{"given":"Daniel","family":"Wendling","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9dric","family":"Lukas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e9ment","family":"Prati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Claudepierre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laure","family":"Gossec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Goupille","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Hudry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinne","family":"Miceli-Richard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Molto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thao","family":"Pham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Saraux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxime","family":"Dougados","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jbspin.2018.01.006_bib0350","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1056\/NEJMra1406182","article-title":"Ankylosing spondylitis and axial spondyloarthritis","volume":"374","author":"Taurog","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jbspin.2018.01.006_bib0355","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.jbspin.2015.06.006","article-title":"Spondyloarthritis: a concept or a disease?","volume":"82","author":"Wendling","year":"2015","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.jbspin.2018.01.006_bib0360","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0140-6736(16)31591-4","article-title":"Axial spondyloarthritis","volume":"390","author":"Sieper","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jbspin.2018.01.006_bib0365","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1056\/NEJMra1505557","volume":"376","author":"Ritchlin","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jbspin.2018.01.006_bib0370","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.jbspin.2013.12.002","article-title":"Recommendations of the French Society for Rheumatology (SFR) on the everyday management of patients with spondyloarthritis","volume":"81","author":"Wendling","year":"2014","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.jbspin.2018.01.006_bib0375","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1136\/annrheumdis-2016-210770","article-title":"2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis","volume":"76","author":"van der Heijde","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2018.01.006_bib0380","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1136\/annrheumdis-2015-208337","article-title":"European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update","volume":"75","author":"Gossec","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2018.01.006_bib0385","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/art.39573","article-title":"Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis","volume":"68","author":"Coates","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jbspin.2018.01.006_bib0390","doi-asserted-by":"crossref","first-page":"e000397","DOI":"10.1136\/rmdopen-2016-000397","article-title":"Efficacy and safety of non-pharmacological and non-biological pharmacological treatment: a systematic literature review informing the 2016 update of the ASAS\/EULAR recommendations for the management of axial spondyloarthritis","volume":"3","author":"Regel","year":"2017","journal-title":"RMD Open"},{"key":"10.1016\/j.jbspin.2018.01.006_bib0395","doi-asserted-by":"crossref","first-page":"e000396","DOI":"10.1136\/rmdopen-2016-000396","article-title":"Efficacy and safety of biological and targeted-synthetic DMARDs: a systematic literature review informing the 2016 update of the ASAS\/EULAR recommendations for the management of axial spondyloarthritis","volume":"3","author":"Sepriano","year":"2017","journal-title":"RMD Open"},{"key":"10.1016\/j.jbspin.2018.01.006_bib0400","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1136\/annrheumdis-2015-208466","article-title":"Pharmacological treatment of psoriatic arthritis: a systematic literature review for the 2015 update of the EULAR recommendations for the management of psoriatic arthritis","volume":"75","author":"Ramiro","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2018.01.006_bib0405","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.jbspin.2015.02.017","article-title":"Spondyloarthritis: criteria, limitations, and perspectives throughout history","volume":"82","author":"Lekpa","year":"2015","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.jbspin.2018.01.006_bib0410","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.jbspin.2017.01.010","article-title":"Classification criteria versus physician's opinion for considering a patient with inflammatory back pain as suffering from spondyloarthritis","volume":"85","author":"Gazeau","year":"2018","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.jbspin.2018.01.006_bib0415","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.jbspin.2016.05.012","article-title":"Collection and management of selected comorbidities and their risk factors in chronic inflammatory rheumatic diseases in daily practice in France","volume":"83","author":"Gossec","year":"2016","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.jbspin.2018.01.006_bib0420","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1136\/annrheumdis-2013-204858","article-title":"Diagnostic delay of more than 6 months contributes to poor radiographic and functional outcome in psoriatic arthritis","volume":"74","author":"Haroon","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2018.01.006_bib0425","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1136\/annrheumdis-2016-210775","article-title":"Anti-TNF-induced remission in very early peripheral spondyloarthritis: the CRESPA study","volume":"76","author":"Carron","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2018.01.006_bib0430","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1136\/annrheumdis-2012-202608","article-title":"Smoking and delay to diagnosis are associated with poorer functional outcome in psoriatic arthritis","volume":"72","author":"Tillett","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2018.01.006_bib0435","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1136\/annrheumdis-2012-201972","article-title":"Early psoriatic arthritis: short symptom duration, male gender and preserved physical functioning at presentation predict favourable outcome at 5-year follow-up. Results from the Swedish Early Psoriatic Arthritis Register (SwePsA)","volume":"73","author":"Theander","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2018.01.006_bib0440","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.jbspin.2016.06.005","article-title":"Diagnostic delay in axial spondyloarthritis: a cross-sectional study of 432\u00a0patients","volume":"84","author":"Masson Behar","year":"2017","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.jbspin.2018.01.006_bib0445","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/annrheumdis-2017-211734","article-title":"Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force","volume":"77","author":"Smolen","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2018.01.006_bib0450","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jbspin.2015.08.015","article-title":"Remission in axial spondyloarthritis: the ultimate treatment goal?","volume":"83","author":"Wendling","year":"2016","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.jbspin.2018.01.006_bib0455","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1016\/S0140-6736(15)00347-5","article-title":"Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomized controlled trial","volume":"386","author":"Coates","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jbspin.2018.01.006_bib0460","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1136\/annrheumdis-2014-205178","article-title":"Higher disease activity leads to more structural damage in the spine in ankylosing spondylitis: 12-year longitudinal data from the OASIS cohort","volume":"73","author":"Ramiro","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2018.01.006_bib0465","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1136\/annrheumdis-2016-209209","article-title":"High disease activity according to the ankylosing spondylitis disease activity score is associated with accelerated radiographic spinal progression in patients with early axial spondyloarthritis: results from the German spondyloarthritis Inception Cohort","volume":"75","author":"Poddubnyy","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2018.01.006_bib0470","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1136\/annrheumdis-2015-207507","article-title":"Disease activity in psoriatic arthritis (PsA): defining remission and treatment success using the DAPSA score","volume":"75","author":"Schoels","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2018.01.006_bib0475","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.3899\/jrheum.151491","article-title":"The effect of the presence of fibromyalgia on common clinical disease activity indices in patients with psoriatic arthritis: a cross-sectional study","volume":"43","author":"Brikman","year":"2016","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jbspin.2018.01.006_bib0480","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1002\/art.40185","article-title":"Co-occurrence and characteristics of patients with axial spondyloarthritis who meet criteria for fibromyalgia: results from a UK national register (BSRBR-AS)","volume":"77","author":"Macfarlane","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jbspin.2018.01.006_bib0485","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1093\/rheumatology\/kex079","article-title":"The problem in differentiation between psoriatic-related polyenthesitis and fibromyalgia","volume":"57","author":"Marchesoni","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jbspin.2018.01.006_bib0490","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.3899\/jrheum.160104","article-title":"Fibromyalgia in spondyloarthritis: effect on disease activity assessment in clinical practice","volume":"43","author":"Wach","year":"2016","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jbspin.2018.01.006_bib0495","first-page":"50","article-title":"Evaluation of whether extremely high enthesitis or Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) scores suggest fibromyalgia and confound the anti-TNF response in early non-radiographic axial spondyloarthritis","volume":"35 Suppl. 105","author":"Dougados","year":"2017","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.jbspin.2018.01.006_bib0500","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1007\/s10067-016-3353-3","article-title":"Spondyloarthritis and fibromyalgia: interfering association or differential diagnosis?","volume":"35","author":"Wendling","year":"2016","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.jbspin.2018.01.006_bib0505","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.semarthrit.2016.11.004","article-title":"The effect of smoking on clinical and structural damage in patients with axial spondyloarthritis: a systematic literature review","volume":"46","author":"Villaverde-Garc\u00eda","year":"2017","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2018.01.006_bib0510","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1002\/acr.23157","article-title":"Disease severity in never smokers, ex-smokers, and current smokers with axial spondyloarthritis: results from the Scotland Registry for Ankylosing Spondylitis","volume":"69","author":"Jones","year":"2017","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.jbspin.2018.01.006_bib0515","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.jbspin.2016.06.004","article-title":"Remission is related to CRP and smoking in early axial spondyloarthritis. The DESIR cohort","volume":"84","author":"Wendling","year":"2017","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.jbspin.2018.01.006_bib0520","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1136\/annrheumdis-2014-205389","article-title":"Association between tobacco smoking and response to tumour necrosis factor \u03b1 inhibitor treatment in psoriatic arthritis: results from the DANBIO registry","volume":"74","author":"H\u00f8jgaard","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2018.01.006_bib0525","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s10067-014-2742-8","article-title":"Smoking is associated with a worse self-reported health status in patients with psoriatic arthritis: data from a Swedish population-based cohort","volume":"34","author":"Bremander","year":"2015","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.jbspin.2018.01.006_bib0530","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.semarthrit.2015.08.003","article-title":"Exercise for ankylosing spondylitis: an evidence-based consensus statement","volume":"45","author":"Millner","year":"2016","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2018.01.006_bib0535","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1007\/s10067-015-2913-2","article-title":"Effects of home-based exercise intervention on health-related quality of life for patients with ankylosing spondylitis: a meta-analysis","volume":"34","author":"Liang","year":"2015","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.jbspin.2018.01.006_bib0540","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1136\/annrheumdis-2015-208174","article-title":"Prevalence of comorbidities and evaluation of their screening in spondyloarthritis: results of the international cross-sectional ASAS-COMOSPA study","volume":"75","author":"Molt\u00f3","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2018.01.006_bib0545","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1136\/annrheumdis-2016-209775","article-title":"EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015\/2016 update","volume":"76","author":"Agca","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2018.01.006_bib0550","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1136\/annrheumdis-2015-207677","article-title":"Comparative efficacy of non-steroidal anti-inflammatory drugs in ankylosing spondylitis: a Bayesian network meta-analysis of clinical trials","volume":"75","author":"Wang","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2018.01.006_bib0555","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1093\/rheumatology\/keu438","article-title":"Maintenance of improvement in spinal mobility, physical function and quality of life in patients with ankylosing spondylitis after 5 years in a clinical trial of adalimumab","volume":"54","author":"van der Heijde","year":"2015","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jbspin.2018.01.006_bib0560","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1186\/s13075-016-1200-1","article-title":"Serum biomarkers and changes in clinical\/MRI evidence of golimumab-treated patients with ankylosing spondylitis: results of the randomized, placebo-controlled GO-RAISE study","volume":"18","author":"Inman","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jbspin.2018.01.006_bib0565","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1136\/annrheumdis-2012-203091","article-title":"A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study","volume":"72","author":"Park","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2018.01.006_bib0570","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1056\/NEJMoa1505066","article-title":"Measure 1 study group; measure 2 Study group. Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis","volume":"373","author":"Baeten","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jbspin.2018.01.006_bib0575","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1002\/acr.23233","article-title":"Measure 2 Study group. Secukinumab and sustained improvement in signs and symptoms of patients with active ankylosing spondylitis through two years: results from a phase III study","volume":"69","author":"Marzo-Ortega","year":"2017","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.jbspin.2018.01.006_bib0580","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1136\/annrheumdis-2016-209730","article-title":"Measure 1 study group. Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study","volume":"76","author":"Braun","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2018.01.006_bib0585","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1136\/annrheumdis-2016-210023","article-title":"Measure 2 Study group. Secukinumab efficacy in anti-TNF-naive and anti-TNF-experienced subjects with active ankylosing spondylitis: results from the Measure 2 Study group","volume":"76","author":"Sieper","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2018.01.006_bib0590","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1136\/annrheumdis-2012-201766","article-title":"Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomized placebo-controlled trial (ABILITY-1)","volume":"72","author":"Sieper","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2018.01.006_bib0595","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1002\/art.39257","article-title":"A randomized, double-blind, placebo-controlled, sixteen-week study of subcutaneous golimumab in patients with active nonradiographic axial spondyloarthritis","volume":"67","author":"Sieper","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jbspin.2018.01.006_bib0600","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1002\/art.38721","article-title":"Symptomatic efficacy of etanercept and its effects on objective signs of inflammation in early nonradiographic axial spondyloarthritis: a multicenter, randomized, double-blind, placebo-controlled trial","volume":"66","author":"Dougados","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jbspin.2018.01.006_bib0605","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1002\/art.39008","article-title":"Randomized controlled trial of adalimumab in patients with nonpsoriatic peripheral spondyloarthritis","volume":"67","author":"Mease","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jbspin.2018.01.006_bib0610","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1136\/annrheumdis-2013-204741","volume":"73","author":"Kavanaugh","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2018.01.006_bib0615","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1136\/annrheumdis-2013-204655","volume":"73","author":"Ritchlin","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2018.01.006_bib0620","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1002\/acr.22645","article-title":"PSUMMIT 1 Study group. Maintenance of clinical efficacy and radiographic benefit through two years of ustekinumab therapy in patients with active psoriatic arthritis: results from a randomized, placebo-controlled phase III trial","volume":"67","author":"Kavanaugh","year":"2015","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.jbspin.2018.01.006_bib0625","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1056\/NEJMoa1412679","article-title":"Secukinumab inhibition of interleukin-17A in patients with psoriatic arthritis","volume":"373","author":"Mease","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jbspin.2018.01.006_bib0630","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/S0140-6736(15)61134-5","article-title":"Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (future 2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"386","author":"McInnes","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jbspin.2018.01.006_bib0635","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1002\/art.39685","article-title":"Brief report: secukinumab provides significant and sustained inhibition of joint structural damage in a phase III study of active psoriatic arthritis","volume":"68","author":"van der Heijde","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jbspin.2018.01.006_bib0640","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.3899\/jrheum.160275","article-title":"Efficacy of subcutaneous secukinumab in patients with active psoriatic arthritis stratified by prior tumor necrosis factor inhibitor use: results from the randomized placebo-controlled future 2 study","volume":"43","author":"Kavanaugh","year":"2016","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jbspin.2018.01.006_bib0645","doi-asserted-by":"crossref","first-page":"e000181","DOI":"10.1136\/rmdopen-2015-000181","article-title":"Comparative effectiveness of biologic monotherapy versus combination therapy for patients with psoriatic arthritis: results from the Corrona registry","volume":"1","author":"Mease","year":"2015","journal-title":"RMD Open"},{"key":"10.1016\/j.jbspin.2018.01.006_bib0650","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1136\/annrheumdis-2013-205056","article-title":"Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor","volume":"73","author":"Kavanaugh","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2018.01.006_bib0655","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.3899\/jrheum.151376","article-title":"A phase III randomized, controlled trial of apremilast in patients with psoriatic arthritis: results of the PALACE 2 trial","volume":"43","author":"Cutolo","year":"2016","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jbspin.2018.01.006_bib0660","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1136\/annrheumdis-2015-207963","article-title":"Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3)","volume":"75","author":"Edwards","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2018.01.006_bib0665","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.jbspin.2016.01.004","article-title":"TNF\u03b1 antagonist therapy in axial spondyloarthritis: can we do better?","volume":"83","author":"Prati","year":"2016","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.jbspin.2018.01.006_bib0670","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.semarthrit.2017.04.005","article-title":"Switching tumor necrosis factor inhibitors in the treatment of axial spondyloarthritis","volume":"47","author":"Deodhar","year":"2017","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2018.01.006_bib0675","doi-asserted-by":"crossref","first-page":"81","DOI":"10.3899\/jrheum.150744","article-title":"Effectiveness and feasibility associated with switching to a second or third TNF inhibitor in patients with psoriatic arthritis: a cohort study from southern Sweden","volume":"43","author":"Kristensen","year":"2016","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jbspin.2018.01.006_bib0680","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.jbspin.2016.03.002","article-title":"Kinases inhibitors and small molecules: a new treatment tool for axial spondyloarthropathy?","volume":"83","author":"Wendling","year":"2016","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.jbspin.2018.01.006_bib0685","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1517\/13543784.2016.1116519","article-title":"An overview of investigational new drugs for treating ankylosing spondylitis","volume":"25","author":"Wendling","year":"2016","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.jbspin.2018.01.006_bib0690","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1136\/annrheumdis-2014-205202","article-title":"A tailored approach to reduce dose of anti-TNF drugs may be equally effective, but substantially less costly than standard dosing in patients with ankylosing spondylitis over 1 year: a propensity score-matched cohort study","volume":"75","author":"Z\u00e1vada","year":"2016","journal-title":"Ann Rheum Dis"}],"container-title":["Joint Bone Spine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1297319X18300083?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1297319X18300083?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T21:49:50Z","timestamp":1719870590000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1297319X18300083"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":69,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["S1297319X18300083"],"URL":"https:\/\/doi.org\/10.1016\/j.jbspin.2018.01.006","relation":{},"ISSN":["1297-319X"],"issn-type":[{"value":"1297-319X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"2018 update of French Society for Rheumatology (SFR) recommendations about the everyday management of patients with spondyloarthritis","name":"articletitle","label":"Article Title"},{"value":"Joint Bone Spine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbspin.2018.01.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Soci\u00e9t\u00e9 fran\u00e7aise de rhumatologie. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}